Psoriatic Arthritis: Developments in 2025

TL;DR

This review discusses recent developments in understanding and treating psoriatic arthritis, focusing on early diagnosis and personalized management to improve patient outcomes.

Contribution

The paper provides a comprehensive overview of 2025 advancements in PsA, including risk identification and new therapeutic approaches.

Findings

New insights into the transition from psoriasis to psoriatic arthritis have been identified.

Advancements in pathogenesis understanding are leading to more individualized treatment protocols.

Improved diagnostic methods are helping prevent functional disability in PsA patients.

Abstract

Psoriatic arthritis (PsA) a complex, multifaceted autoimmune disease involving the skin and joints, presents a diagnostic and therapeutic challenge due to its heterogenous nature and existence of comorbidities. Early diagnosis is essential to prevent functional disability and achieve disease remission. The previous year has seen further advancements in the better understanding of PsA that include identifying patients at risk and the phases of transition from psoriasis (PsO) to PsA as well as new insights in pathogenesis and the development of newer treatments and therapeutic protocols. These developments are paving the way for more individualised management protocols aiming for further improvement in the quality of life for patients living with PsA. In this narrative review article, we reviewed the literature from major scientific databases for PsA from June 2024 to September 2025.